Patents by Inventor Sören Berg
Sören Berg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190248896Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: April 29, 2019Publication date: August 15, 2019Inventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Publication number: 20170281809Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: June 16, 2017Publication date: October 5, 2017Inventors: PETRUS JOHANNES LOUIS SPEE, SOEREN BERG PADKAER
-
Patent number: 9708403Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: March 23, 2015Date of Patent: July 18, 2017Assignees: NOVO NORDISK A/S, INNATE PHARMAInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Petrus Johannes Louis Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 9683041Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: GrantFiled: November 20, 2014Date of Patent: June 20, 2017Assignee: NOVO NORDISK A/SInventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Publication number: 20160046712Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: ApplicationFiled: March 23, 2015Publication date: February 18, 2016Inventors: Søren Berg Padkær, Peter Andreas, Nicolai, Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Patent number: 9018366Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 18, 2013Date of Patent: April 28, 2015Assignees: Innate Pharma S.A.S, Novo Nordisk A/SInventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Publication number: 20150071929Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: November 20, 2014Publication date: March 12, 2015Inventors: PETRUS JOHANNES LOUIS SPEE, SOEREN BERG PADKAER
-
Patent number: 8901283Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: GrantFiled: May 22, 2012Date of Patent: December 2, 2014Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Soeren Berg Padkaer
-
Patent number: 8796427Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.Type: GrantFiled: January 23, 2009Date of Patent: August 5, 2014Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Jianhe Chen, Søren Berg Padkjær, Jing Su, Jinchao Zhang, Jiujiu Yu
-
Publication number: 20140193430Abstract: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: December 13, 2013Publication date: July 10, 2014Applicants: NOVO NORDISK A/S, UNIVERSITY OF GENOA, BRISTOL-MYERS SQUIBB COMPANYInventors: SØREN BERG PADKJAER, ALESSANDRO MORETTA, MARIELLA DELLA CHIESA, PASCALE ANDRE, LAURENT GAUTHIER, PETER ANDREAS NICOLAI RUMERT WAGTMANN
-
Patent number: 8613926Abstract: The present invention concerns human antibodies recognizing the human C5a receptor. By binding to C5aR the antibodies inhibit C5a signalling, whereby the pro-inflammatory signal is inhibited. Based on the role of C5a and its receptor in stimulation of inflammation the invention further relates to therapeutic use of said human anti-C5aR antibodies and in particular in relation to treatment of immunological disorders.Type: GrantFiled: June 6, 2012Date of Patent: December 24, 2013Assignee: Novo Nordisk A/SInventors: Kristian Kjaergaard, Soeren Lund, Soeren Berg Padkjaer
-
Patent number: 8435388Abstract: The invention is a method for obtaining a reactive sputtering process with a reduced or eliminated hysteresis behavior. This is achieved by employing a target made from a mixture of metal and compound materials. In the method according to the present invention, the fraction of compound material is large enough to eliminate or significantly reduce the hysteresis behavior of the reactive sputtering process and enable a stable deposition of compound films at a rate significantly higher than what is possible from a target completely made from compound material.Type: GrantFiled: October 31, 2006Date of Patent: May 7, 2013Assignee: Cardinal CG CompanyInventors: Klaus Hartig, Sören Berg, Tomas Nyberg
-
Patent number: 8388970Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: October 2, 2008Date of Patent: March 5, 2013Assignees: Novo Nordisk A/S, Innate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Andreas Nicolai Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard, Anders Svensson
-
Publication number: 20120237510Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: ApplicationFiled: May 22, 2012Publication date: September 20, 2012Applicant: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær
-
Publication number: 20120208237Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: ApplicationFiled: January 11, 2012Publication date: August 16, 2012Applicants: Innate Pharma S.A.S, Novo-Nordisk A/S - Novo AlleInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 8222376Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.Type: GrantFiled: January 6, 2006Date of Patent: July 17, 2012Assignees: Novo Nordisk A/S, Inmate Pharma S.A.S.Inventors: Søren Berg Padkær, Peter Reumert Wagtmann, Pieter Spee, Stefan Zahn, Kristian Kjærgaard
-
Patent number: 8206709Abstract: Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.Type: GrantFiled: June 28, 2007Date of Patent: June 26, 2012Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær
-
Patent number: 8119775Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.Type: GrantFiled: October 2, 2008Date of Patent: February 21, 2012Assignees: University of Genoa, Innate Pharma S.A.S., Novo Nordisk A/SInventors: Alessandro Moretta, Mariella Della Chiesa, Pascale Andre, Laurent Gauthier, Francois Romagné, Peter Andreas Nicolai Reumert Wagtmann, Ivan Svendsen, Stefan Zahn, Anders Svensson, Matthias Thórólfsson, Søren Berg Padkær, Kristian Kjaergaard, Pieter Spee, Michael Wilken
-
Patent number: 7932055Abstract: Soluble versions of heterodimeric receptors, e.g., CD94/NKG2 receptors, and methods of producing and using such constructs, are described. The constructs comprise soluble fragments of, each receptor monomer, and some constructs further comprise at least one immunoglobulin Fc domain. Exemplary constructs are those wherein (1) each soluble fragment is linked to an immunoglobulin Fc domain, which are then allowed to dimerize, (2) each soluble fragment is linked to an immunoglobulin Fc domain mutated to promote forced dimerization with the correct counterpart, and (3) single-chain constructs where the monomeric receptor fragments are linked, and the C-terminal fragment is linked to an Fc domain.Type: GrantFiled: June 22, 2007Date of Patent: April 26, 2011Assignee: Novo Nordisk A/SInventors: Petrus Johannes Louis Spee, Søren Berg Padkær, Birgitte Nissen Friedrichsen, Inga Sig Nielsen Nørby
-
Publication number: 20110052606Abstract: The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies.Type: ApplicationFiled: January 23, 2009Publication date: March 3, 2011Inventors: Petrus Johannes Louis Spee, Jianhe Chen, Søren Berg Padkjaer, Jing Su, Jinchao Zhang, Jiujiu Yu